A Case Report of a Hemodialysis Patient With Coagulation Factor XI and Factor XII Deficiencies.

Autor: Li X; Department of Nephrology, Hospital of University of Traditional Chinese Medicine, Chengdu, China.; School of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China., Wang Y; The 2nd Department of Foot and Ankle, Sichuan Provincial Orthopedics Hospital, Chengdu, China.
Jazyk: angličtina
Zdroj: Seminars in dialysis [Semin Dial] 2024 Nov-Oct; Vol. 37 (6), pp. 451-455. Date of Electronic Publication: 2024 Aug 18.
DOI: 10.1111/sdi.13219
Abstrakt: Coagulation Factor XI (FXI) and Factor XII (FXII) deficiencies are rare. FXI deficiency is associated with a bleeding disorder, while FXII deficiency is not, but both can cause chronic prolongation of activated partial thromboplastin time and impair thrombus formation, posing great challenges for hemodialysis anticoagulation. Traditionally, heparin or low-molecular-weight heparins (LMWHs) are not considered a safe anticoagulation option for patients with increased bleeding risk. In this context, FXI and FXII have received substantial attention as targets for new anticoagulants. We present the case of a 68-year-old woman with combined FXI and FXII deficiencies who successfully underwent hemodialysis with anticoagulation using a low dose of LMWHs. This case highlights that FXI and FXII deficiencies are associated with anticoagulant effects, which can reduce the dosage of anticoagulant during hemodialysis. With careful monitoring, an appropriate dosage of LMWHs is still an acceptable option for patients with a bleeding risk.
(© 2024 Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: